Univ.-Prof. Dr. rer. nat. Eckhard Lammert

Selected Publications

• Henning C, Branopolski A, Schuler D, Dimitroulis D, Huelsemann P, Nicolaus C, Sansone R, Ludolf Postma J, Eberhard D, Le Noble F, Kelm M, Lammert E, Heiss C 2019. Requirement of β1 integrin for endothelium-dependent vasodilation and collateral formation in hindlimb ischemia. Sci Rep. 9. https://doi.org/10.1038/s41598-019-53137-x
• Urner S, Planas-Paz L, Hilger LS, Henning C, Branopolski A, Kelly-Goss M, Stanczuk L, Pitter B, Montanez E, Peirce SM, Mäkinen T, Lammert E 2019. Identification of ILK as a critical regulator of VEGFR3 signalling and lymphatic vascular growth. EMBO J. 38. https://doi.org/10.15252/embj.201899322
• Lorenz L, Axnick J, Buschmann T, Henning C, Urner S, Fang S, Nurmi H, Eichhorst N, Holtmeier R, Bódis K, Hwang J-H, Müssig K, Eberhard D, Stypmann J, Kuss O, Roden M, Alitalo K, Häussinger D, Lammert E 2018. Mechanosensing by β1 integrin induces angiocrine signals for liver growth and survival. Nature. 562: 128-132. https://doi.org/10.1038/s41586-018-0522-3
• Welters A, Klüppel C, Mrugala J, Wörmeyer L, Meissner T, Mayatepek E, Heiss C, Eberhard D, Lammert E 2017. NMDAR antagonists for the treatment of diabetes mellitus-Current status and future directions. Diabetes Obes Metab. 19: 95-106. https://doi.org/10.1111/dom.13017
• Otter S, Lammert E 2016. Exciting Times for Pancreatic Islets: Glutamate Signaling in Endocrine Cells. Trends Endocrinol Metab. 27: 177-88. https://doi.org/10.1016/j.tem.2015.12.004
• Belgardt B-F, Lammert E 2016. DYRK1A: A Promising Drug Target for Islet Transplant-Based Diabetes Therapies. Diabetes. 65: 1496-8. https://doi.org/10.2337/dbi16-0013